Evidence map›Paper›PMID 23322746›Full record

ArticleProtein engineering, design & selection : PEDS2013

Evaluating the use of Apo-neocarzinostatin as a cell penetrating protein.

Paul Moody, Fabienne Burlina, Stephen R Martin, Rachel E Morgan, John Offer, Mark E B Smith, Justin E Molloy, Stephen Caddick

Open access · hybridAbstract readEvaluation Study
In one paragraph

Article in Protein engineering, design & selection : PEDS, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 7 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Paul MoodyDepartment of Chemistry, University College London, Gordon Street, London WC1H 0AJ, UK.
Fabienne Burlina
Stephen R Martin
Rachel E Morgan
John Offer
Mark E B Smith
Justin E Molloy
Stephen Caddick
University College London · GBSorbonne Université · FR

Funding

Medical Research Council MC_U117570592Medical Research Council MC_U117592730Wellcome TrustWellcome Trust 090145/Z/09/Z
6 · The paper itself

Abstract

Protein-ligand complex neocarzinostatin (NCS) is a small, thermostable protein-ligand complex that is able to deliver its ligand cargo into live mammalian cells where it induces DNA damage. Apo-NCS is able to functionally display complementarity determining regions loops, and has been hypothesised to act as a cell-penetrating protein, which would make it an ideal scaffold for cell targeting, and subsequent intracellular delivery of small-molecule drugs. In order to evaluate apo-NCS as a cell penetrating protein, we have evaluated the efficiency of its internalisation into live HeLa cells using matrix-assisted laser-desorption ionization-time-of-flight mass spectrometry and fluorescence microscopy. Following incubation of cells with apo-NCS, we observed no evidence of internalisation.

Indexed as

Cell-Penetrating PeptidesDNA DamageHeLa CellsHumansKineticsLigandsMicroscopy, FluorescenceMultiprotein ComplexesProtein BindingZinostatinCell-Penetrating PeptidesLigandsMultiprotein ComplexesZinostatin

Identifiers

PMID23322746
PMCPMC3601848
OpenAlexW2134145743

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.